ReviewJournal of clinical medicine2024
Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Sodium-glucose cotransporter-2 inhibitors and risk of diabetic retinopathy in type 2 diabetes: a network meta-analysis of randomised clinical trials.International journal of clinical pharmacy · 2026Pooled it
- Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases.Nature communications · 2026Pooled it
- SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis.International ophthalmology · 2025Pooled it
- Therapeutic potential of GLP-1 receptor agonists and SGLT2 inhibitors in diabetic neuropathy: a critical appraisal.Diabetology & metabolic syndrome · 2026Review
- HbA1c kinetics as a prognostic marker of ophthalmic risk in GLP-1 receptor agonist therapy.Metabolism open · 2026Review
- The Effects of GLP-1 Receptor Agonists on Retinal Microvascular Alterations.Biomedicines · 2026Review
- Novel Small Molecule GLP-1R Agonists Based on 1Molecules (Basel, Switzerland) · 2026Article
- GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes.JAMA network open · 2025Article
- Semaglutide and the Retina.Journal of diabetes · 2025Article
- Diabetes Renders Photoreceptors Susceptible to Retinal Ischemia-Reperfusion Injury.Investigative ophthalmology & visual science · 2024Article
- Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.Molecular biomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.